Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

• Published in: Neurology and therapy Vol. 13; no. 1; pp. 85 - 105
• Main Authors: Schwedt, Todd J., Myers Oakes, Tina M., Martinez, James M., Vargas, Bert B., Pandey, Hitendra, Pearlman, Eric M., Richardson, Diane R., Varnado, Oralee J., Cobas Meyer, Michael, Goadsby, Peter J.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.02.2024; Adis, Springer Healthcare
• Subjects: Calcitonin gene-related peptide (CGRP); CGRP antagonist; Galcanezumab; Gepant; Head-to-head; Internal Medicine; Medicine; Medicine & Public Health; Migraine; NCT; NCT05127486; Neurology; Original Research; Prevention; Rimegepant; Comparative efficacy; Calcitonin gene-related peptide (CGRP); Migraine; CGRP antagonist; Head-to-head; Galcanezumab; Gepant; Clinical study

Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study of two CGRP antagonists, galcanezumab (monoclonal antibody) versus rimegepa...